Two medicines, side by side
Ivabradine vs carvedilol
Ivabradine and carvedilol are both labeled for heart failure. Drugs@FDA records approvals of ivabradine since 2015 and of carvedilol since 1995. Pharmacies paid $0.761 per ivabradine HCl 5 mg tablet and $0.0179 per carvedilol 6.25 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker and carvedilol an alpha-adrenergic blocker.
Check it at the source: the ivabradine FDA label on DailyMed (effective November 10, 2025); the carvedilol FDA label on DailyMed (effective July 31, 2026).
Highlights of the ivabradine record
Ivabradine (Corlanor) · label of November 10, 2025
Used for
From the label: indicationsINDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. […]
On the market
- Earliest approval on file
- April 15, 2015
- Generic labelers
- 11 labelers
- Pharmacy cost
- $0.761 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 2
Highlights of the carvedilol record
Carvedilol (Coreg) · label of July 31, 2026
Used for
From the label: indicationsINDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]
On the market
- Earliest approval on file
- September 14, 1995
- Generic labelers
- 41 labelers
- Pharmacy cost
- $0.0179 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 22
Source: FDA drug labels via openFDA (Ivabradine label of November 10, 2025, Carvedilol label of July 31, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do ivabradine and carvedilol differ on the record?
In FDA's classes, ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker and carvedilol an alpha-adrenergic blocker.
How each works, in its label's words: Ivabradine, “Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate.”; Carvedilol, “COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers …”
Half-life, in each label's words: Ivabradine, “Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 …”; Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”
Generics: ivabradine since 2021; carvedilol since 2007 (Drugs@FDA).
| Ivabradine | Carvedilol | |
|---|---|---|
| Labeled for | Heart failure | Heart failure, High blood pressure |
| Pharmacologic class | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker | alpha-Adrenergic Blocker, beta-Adrenergic Blocker |
| How it works (label) | Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. | COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. |
| Half-life (label) | Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours. | Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. |
| Earliest approval on file (Drugs@FDA) | April 15, 2015 | September 14, 1995 |
| First generic approved | December 30, 2021 | September 5, 2007 |
| Generic labelers (NDC) | 11 labelers | 41 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.761 per tablet (Ivabradine HCl 5 mg tablet) | $0.0179 per tablet (Carvedilol 6.25 mg tablet) |
| 12-month price change | -75% | -4% |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | No current entry |
| Recalls recorded | 2 | 22 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,817 | 137,029 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to ivabradine
- every medicine labeled for the same conditions